East Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy
Guixin Wu,Liwen Liu,Zhengyang Zhou,Jie Liu,Bo Wang,Jieyun Ruan,Qianli Yang,Mohammed Kanchwala,Peng Dai,Channa Zhang,Dong Wang,Lianming Kang,Shuiyun Wang,Hui Ren,Yubao Zou,Chao Xing,Lingyun Song,Jizheng Wang
DOI: https://doi.org/10.1161/circulationaha.120.050384
IF: 37.8
2020-01-01
Circulation
Abstract:HomeCirculationVol. 142, No. 21East Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBEast Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy Guixin Wu, MD Liwen Liu, MD Zhengyang Zhou, PhD Jie Liu, MD Bo Wang, MS Jieyun Ruan, MD Qianli Yang, MS Mohammed Kanchwala, MS Penggao Dai, PhD Channa Zhang, BS Dong Wang, MD Lianming Kang, MD Shuiyun Wang, MD Rutai Hui, MD, PhD Yubao Zou, MD Chao Xing, PhD Lei Song, MD, PhD Jizheng WangPhD Guixin WuGuixin Wu State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Liwen LiuLiwen Liu Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Zhengyang ZhouZhengyang Zhou Department of Biostatistics and Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth (Z.Z.). , Jie LiuJie Liu https://orcid.org/0000-0001-7627-2836 State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Bo WangBo Wang Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Jieyun RuanJieyun Ruan State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Qianli YangQianli Yang Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Mohammed KanchwalaMohammed Kanchwala https://orcid.org/0000-0001-6035-2970 Eugene McDermott Center for Human Growth and Development (M.K., C.X.), University of Texas Southwestern Medical Center, Dallas. , Penggao DaiPenggao Dai National Engineering Research Center for Miniaturized Detection Systems, College of Life Science, Northwest University, Xi'an, Shaanxi, China (P.D.). , Channa ZhangChanna Zhang State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Dong WangDong Wang Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Lianming KangLianming Kang Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Shuiyun WangShuiyun Wang Department of Cardiac Surgery (S.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Rutai HuiRutai Hui State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Yubao ZouYubao Zou State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Chao XingChao Xing Chao Xing, PhD, McDermott Center for Human Growth and Development, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8591. Email E-mail Address: [email protected] https://orcid.org/0000-0002-1838-0502 Eugene McDermott Center for Human Growth and Development (M.K., C.X.), University of Texas Southwestern Medical Center, Dallas. Department of Bioinformatics (C.X.), University of Texas Southwestern Medical Center, Dallas. Department of Population and Data Sciences (C.X.), University of Texas Southwestern Medical Center, Dallas. , Lei SongLei Song Lei Song, MD, PhD, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email E-mail Address: [email protected] State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. National Clinical Research Center of Cardiovascular Diseases (L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Jizheng WangJizheng Wang Jizheng Wang, PhD, State Key Laboratory of Cardiovascular Disease, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email E-mail Address: [email protected] https://orcid.org/0000-0002-2961-524X State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Originally published20 Oct 2020https://doi.org/10.1161/CIRCULATIONAHA.120.050384Circulation. 2020;142:2086–2089Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder characterized by unexplained left ventricular hypertrophy.1 Although considered as a dominant Mendelian disease mainly caused by rare pathogenic variants in sarcomere genes, the genetic underpinnings of nearly half of patients remain unsolved.2 Increasing evidence implies that HCM has a more complex genetic architecture.3 We identified an East Asian–specific common missense variant in TNNI3 (rs3729712) associated with HCM in an exome-wide case–control association study of Chinese origin and replicated the finding in 3 independent studies (P=5.80×10–22).Both the discovery study (986 cases and 761 controls) and the Beijing replication study4 (529 cases and 307 controls) were from Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing. The other 2 replication studies, Xi'an-1 (646 cases and 468 controls) and Xi'an-2 (670 cases and 577 controls), were from Xijing Hospital of Fourth Military Medical University, Xi'an, Shaanxi. HCM was diagnosed by the presence of a maximal ventricular wall thickness ≥15 mm, or ≥13 mm in individuals with a family history of HCM, in the absence of any abnormal loading conditions capable of producing such a magnitude of hypertrophy. HCM was excluded in all the controls by a lack of primary left ventricular hypertrophy on echocardiography. The study protocols were approved by the ethics committees of both hospitals. Written informed consent was obtained from each participant. Detailed methods and results are available from the corresponding author on reasonable request and in accordance with the data sharing agreement.The discovery study samples underwent whole exome sequencing. Both single-variant association screen for common variants and gene-based association screen for rare variants were performed. As expected, rare variants in MYH7 and MYBPC3, the 2 most common causal genes of HCM, were greatly enriched in patients (Figure A). There was no novel gene attaining genome-wide significance. The single-variant association screen identified a common variant rs3729712 in TNNI3 (NC_000019:g.55667616G>A; NM_000363:c.235C>T; NP_000354:p.Arg79Cys) associated with HCM (Figure B). The minor allele frequency (MAF) of this variant was significantly higher in patients (0.055) than in controls (0.016), with the odds ratio (95% CI) per risk allele estimated to be 3.31 (2.12, 5.15; P=1.28×10–7). The association was confirmed in each of the 3 replication studies, among which the Beijing replication samples and Xi'an-1 cases were genotyped by a panel sequencing of cardiomyopathy candidate genes, and the Xi'an-1 controls and Xi'an-2 samples by Sanger sequencing. The fixed-effects meta-analysis of all 4 studies estimated the odds ratio (95% CI) per risk allele to be 4.62 (3.39–6.30; Figure C).Download figureDownload PowerPointFigure. Association of TNNI3 rs3729712 with hypertrophic cardiomyopathy (HCM). A, Quantile–quantile plot of the observed P values vs the expected P values for the gene-based rare variants sequence kernel association test in the discovery study. The rare variants include missense, nonsense, splicing, and frameshift variants with Genomic Evolutionary Rate Profiling score ≥2 and minor allele frequency <0.01 in the whole study. There were 16 568 genes containing the qualified rare variants. The dashed line represents the genome-wide significance threshold by Bonferroni correction (0.05/16 568=3.02×10–6). Two genes, MYH7 (P=5.55×10–31) and MYBPC3 (P=3.43×10–9), attained genome-wide significance. B, Quantile–quantile plot of the observed P values vs the expected P values for the single-variant association test by logistic regression in the discovery study. There were 203 455 common variants with minor allele frequency ≥0.01 in the whole study. The dashed line represents the genome-wide significance threshold by Bonferroni correction (0.05/203 455=2.46×10–7). One variant, rs3729712 in TNNI3 (P=1.28×10–7), attained genome-wide significance. C, Fixed-effects meta-analysis of the regression coefficients weighting by the inverse of the variance. The odds ratio (OR) was estimated as the odds of being affected on an increase of 1 copy of the risk allele rs3729712[A] by fitting a logistic regression model. Patients with HCM were classified into SARC+ (pathogenic or likely pathogenic variant identified in a sarcomere gene) and SARC– (no potentially pathogenic variant identified in a sarcomere gene) groups by the presence of any variant of pathogenic, likely pathogenic, or unknown significance in the 8 sarcomere genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, and ACTC1) in the discovery study (495 vs 491), Beijing replication study (226 vs 303), and Xi'an-1 study (342 vs 304). Patients in Xi'an-2 could not be categorized because only rs3729712 was genotyped by Sanger sequencing. The minor allele frequencies (cases vs controls) of rs3729712 in the 4 studies were 0.055 vs 0.016, 0.035 vs 0.0065, 0.055 vs 0.0096, and 0.070 vs 0.0087, respectively; the minor allele frequencies (SARC+ vs SARC–) of rs3729712 in the cases were 0.032 vs 0.076 in the discovery study, 0.017 vs 0.048 in the Beijing replication study, and 0.037 vs 0.076 in the Xi'an-1 study. D, Expression levels of TNNI3 in 21 rs3729712[A] carriers (R79C+) and 21 noncarriers (R79C–). We performed RNA sequencing on myocardial tissue of 42 patients with HCM who underwent Morrow septal myectomy. Expression levels were quantified by transcripts per million (TPM). The error bar indicates 1 SD from the mean. There is no statistical difference between the 2 groups (P>0.05). E, Heatmap of ψ5 values for 5′ intron donor sites identified at TNNI3. ψ (percent-spliced-in) is defined as the proportion of reads supporting a specific splicing event relative to the combined number of reads. Each row corresponds to a patient. Column names indicate the hg38 coordinates of introns tested. There are 9 junctions after filtering for mean counts ≥10 across all samples. Note that junctions chr19:55157134−55157250 and chr19:55157129−55157561 do not belong to the canonical transcript NM_000363. Similar results were obtained for ψ3 but the heatmap was not shown. Neither aberrant splicing event nor different splicing pattern was detected in the R79C– patients compared with the R79C+ patients.We further classified patients into SARC+ and SARC– groups by the presence or absence of any variant of pathogenic, likely pathogenic, or unknown significance in the 8 sarcomere genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, and ACTC1) using the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines,5 and compared the distribution of rs3729712 between groups (Figure C). Compared with controls, the odds ratios (95% CIs) of rs3729712[A] were 5.27 (3.65–7.61) and 2.64 (1.76–3.96) in the SARC– and SARC+ groups, respectively. The rs3729712[A] allele was more frequent in the SARC– group than in the SARC+ group (MAF 0.068 and 0.030, respectively; P=4.63×10–7). The results indicate that SARC– patients likely have a different genetic architecture than do SARC+ patients.The association signal is unlikely attributable to other pathogenic variants in linkage disequilibrium with rs3729712. There were only 3 of 98 cases with rs3729712[A] having a TNNI3 nonsynonymous variant in the discovery study, 0 of 33 in the Beijing replication study, and 1 of 65 in Xi'an-1, which excluded the possibility of rs3729712[A] in linkage disequilibrium with another exonic pathogenic variant. RNA sequencing analysis showed neither altered expression levels (Figure D) nor aberrant splicing events in the myocardium of rs3729712[A] carriers (Figure E), which largely excluded the possibility of rs3729712[A] in linkage disequilibrium with a nonexonic pathogenic variant. Furthermore, we followed up 42 families of probands carrying rs3729712[A], and assessed 69 family members with heterozygous rs3729712[A] but without a sarcomere pathogenic variant, and none of them presented left ventricular hypertrophy.The TNNI3 rs3729712[A] allele appears to be specific to East Asians. In the 1000 Genomes Project and the Asian Admixed Genomes Consortium databases, the variant was only detected in East Asians with MAF of 0.0060 and 0.0092, respectively. In the gnomAD database, MAF was 0.0062 in East Asians, 0.00016 in South Asians, 0.000029 in Latinos, and absent in other populations. The crude MAF of rs3729712 from all patients with HCM in our study (0.055) was significantly higher than the upper limit of MAF (0.016) in one of the subpopulations of East Asians (P=1.44×10–9), which further validates the association signal.This study identified an East Asian–specific common variant TNNI3 rs3729712 associated with HCM. It reveals the existence of non-Mendelian inheritance of HCM and provides important insights into the complexity and ethnic differences of HCM genetic architecture.AcknowledgmentsThe authors thank the patients and their families for participation and the staff members for data collection, sample handling, and genotyping.Sources of FundingThis work was supported by grants from the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CAMS-I2M, 2016-I2M-1-015) and the National Natural Science Foundation of China (81870286 and 81470380).DisclosuresNone.Footnotes*Drs Wu, L. Liu, and Zhou contributed equally.https://www.ahajournals.org/journal/circThis manuscript was sent to Ju Chen, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.Jizheng Wang, PhD, State Key Laboratory of Cardiovascular Disease, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email [email protected]comLei Song, MD, PhD, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email [email protected]comChao Xing, PhD, McDermott Center for Human Growth and Development, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8591. Email chao.[email protected]eduReferences1. Maron BJ.Clinical course and management of hypertrophic cardiomyopathy.N Engl J Med. 2018; 379:655–668. doi: 10.1056/NEJMra1710575CrossrefMedlineGoogle Scholar2. Walsh R, Buchan R, Wilk A, John S, Felkin LE, Thomson KL, Chiaw TH, Loong CCW, Pua CJ, Raphael Cet al.Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.Eur Heart J. 2017; 38:3461–3468. doi: 10.1093/eurheartj/ehw603MedlineGoogle Scholar3. Maron BJ, Maron MS, Maron BA, Loscalzo J.Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week.J Am Coll Cardiol. 2019; 73:1978–1986. doi: 10.1016/j.jacc.2019.01.061CrossrefMedlineGoogle Scholar4. Wang J, Wang Y, Zou Y, Sun K, Wang Z, Ding H, Yuan J, Wei W, Hou Q, Wang Het al.Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy.Eur J Heart Fail. 2014; 16:950–957. doi: 10.1002/ejhf.144CrossrefMedlineGoogle Scholar5. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector Eet al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17:405–424. doi: 10.1038/gim.2015.30CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByWu G, Liu J, Liu M, Huang Q, Ruan J, Zhang C, Wang D, Sun X, Jiang W, Kang L, Wang J and Song L (2021) Truncating Variants in OBSCN Gene Associated With Disease-Onset and Outcomes of Hypertrophic Cardiomyopathy, Circulation: Genomic and Precision Medicine, 14:5, Online publication date: 1-Oct-2021. November 24, 2020Vol 142, Issue 21Article InformationMetrics Download: 1,026 © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.050384PMID: 33078954 Originally publishedOctober 20, 2020 Keywordscardiomyopathy, hypertrophichypertrophygenetic testingAsiansPDF download SubjectsPrecision Medicine